However, FXR's role in pancreatic cancer is conflicting and the fact that in humans it activates a potentially pro-tumorigenic FGF19 emphasizes the needed for more studies that will confirm the positive role of FXR agonists. This evidence concerns the gene NR1H4 and familial pancreatic carcinoma.